The Irwin E. Ginsberg P’84 Aging Research Fund was established as a part of Brown University’s permanent endowment. This Fund supports medical or public health student projects (1) related to aging and (2) mentored by faculty affiliated with the Brown University School of Public Health’s Center for Gerontology & Healthcare Research or Center for Long-Term Care Quality & Innovation.
Together, the Agency for Healthcare Research and Quality and the Patient-Centered Outcomes Research Institute have awarded a 5-year, $5 million grant to create the Learning Health systems training to improve Disability and chronic condition care (LeaHD) center at Brown University.
November 7, 2023 Journal of the American Heart Association
In a cohort study published in the Journal of the American Heart Association of 21,878 older Medicare beneficiaries with multimorbidity residing in nursing homes, Kaley Hayes and her team found that while therapy with standard-dose direct oral anticoagulants was not associated with reductions in mortality or thrombotic events, those on standard dosing experienced 1.4 more major bleeds per 100 person-years compared to those on reduced dosing. Bleeding risks were highest among those aged 80 years or older or those with a body mass index less than 30 kg/m 2 . Given the potential harms and unclear benefits of standard direct oral anticoagulant dosing, our results support the use of reduced-dose direct oral anticoagulants for older adults with multiple comorbidities.
Nearly 95% of older adults in the United States, or 59 million people, have received at least one dose of a COVID-19 vaccine. The messenger-RNA vaccines produced by Pfizer BioNTech and Moderna Inc. are the most widely utilized vaccines, owing to their high degree of efficacy and safety. Published in JAMA Network Open, Dan Harris led a team of researchers in the Center for Gerontology & Healthcare Research at the Brown University School of Public Health to conduct the largest head-to-head comparison of the mRNA vaccines against COVID-19 in older adults and individuals with increased frailty. While both vaccines were exceptionally safe, the mRNA vaccine produced by Moderna Inc. was associated with slightly improved protection against COVID-19 and its negative consequences (e.g., pulmonary embolism) compared to the vaccine produced by Pfizer BioNTech. However, the relative advantages of Moderna Inc were reduced in individuals with greater frailty.